{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:07:25Z","timestamp":1790536045089,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lack of biomarkers for treatment monitoring is listed among the main requirements for next generation assays, as identified globally among tuberculosis (TB) researchers. In this study, we evaluated in a low TB endemic country such as Italy, the effect of preventive therapy on the results obtained in the QuantiFERON TB Plus (QFT-Plus), in a cohort of subjects with latent TB infection (LTBI) and active TB. We found that TB therapy significantly decreased IFN-\u03b3 values and number of responders to TB1- and TB2- peptides stimulation in both LTBI and active TB patients. Stratifying LTBI subjects according to the type of preventive TB therapy used, we found that INH treatment but not INH and RIF significantly decreased IFN-\u03b3 production. Stratifying the active TB patients according the microbiological status, we found that TB therapy significantly decreased IFN-\u03b3 response to antigen present in QFT-Plus test in patients with clinical diagnosis compared to those with a microbiological diagnosis. In conclusions, we demonstrated that TB therapy decreases IFN-\u03b3 level in response to antigen present in QFT-Plus test in LTBI and active TB patients. Future studies are needed to better characterize Mtb-specifc response as a potential marker for monitoring TB therapy and preventive treatment effects.<\/jats:p>","DOI":"10.1038\/s41598-018-33825-w","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T10:14:25Z","timestamp":1539771265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection"],"prefix":"10.1038","volume":"8","author":[{"given":"Elisa","family":"Petruccioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Chiacchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Cuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-2050","authenticated-orcid":false,"given":"Luigi Ruffo","family":"Codecasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Ferrarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Schinin\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"33825_CR1","unstructured":"WHO. Global tuberculosis report 2017, www.who.int\/tb\/publications\/global_report\/en\/ (2017)."},{"key":"33825_CR2","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1183\/13993003.01179-2015","volume":"46","author":"A Matteelli","year":"2015","unstructured":"Matteelli, A. et al. Numbers needed to treat to prevent tuberculosis. Eur. Respir. J. 46, 1838\u20131839 (2015).","journal-title":"Eur. Respir. J."},{"key":"33825_CR3","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","volume":"46","author":"H Getahun","year":"2015","unstructured":"Getahun, H. et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur. Respir. J. 46, 1563\u20131576 (2015).","journal-title":"Eur. Respir. J."},{"key":"33825_CR4","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1183\/09031936.00214014","volume":"45","author":"K Lonnroth","year":"2015","unstructured":"Lonnroth, K. et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur. Respir. J. 45, 928\u2013952 (2015).","journal-title":"Eur. Respir. J."},{"key":"33825_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/resp.13272","volume":"23","author":"D Goletti","year":"2018","unstructured":"Goletti, D., Lee, M. R., Wang, J. Y., Walter, N. & Ottenhoff, T. H. M. Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease. Respirology 23, 455\u2013466 (2018).","journal-title":"Respirology"},{"key":"33825_CR6","doi-asserted-by":"publisher","first-page":"6568","DOI":"10.4081\/idr.2016.6568","volume":"8","author":"D Goletti","year":"2016","unstructured":"Goletti, D., Petruccioli, E., Joosten, S. A. & Ottenhoff, T. H. Tuberculosis Biomarkers: From Diagnosis to Protection. Infect. Dis. Rep. 8, 6568 (2016).","journal-title":"Infect. Dis. Rep."},{"issue":"Suppl 2","key":"33825_CR7","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1093\/infdis\/jiu821","volume":"211","author":"CM Denkinger","year":"2015","unstructured":"Denkinger, C. M. et al. Defining the needs for next generation assays for tuberculosis. J. Infect. Dis. 211(Suppl 2), S29\u201338 (2015).","journal-title":"J. Infect. Dis."},{"key":"33825_CR8","doi-asserted-by":"publisher","first-page":"e0183846","DOI":"10.1371\/journal.pone.0183846","volume":"12","author":"T Chiacchio","year":"2017","unstructured":"Chiacchio, T. et al. Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection. PLoS One 12, e0183846 (2017).","journal-title":"PLoS One"},{"key":"33825_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.diagmicrobio.2016.06.007","volume":"86","author":"E Petruccioli","year":"2016","unstructured":"Petruccioli, E. et al. Use of several immunological markers to model the probability of active tuberculosis. Diagn. Microbiol. Infect. Dis. 86, 169\u2013171 (2016).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"33825_CR10","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.5588\/ijtld.16.0342","volume":"20","author":"L Petrone","year":"2016","unstructured":"Petrone, L. et al. Blood and urine inducible protein 10 as potential markers of disease activity. Int. J. Tuberc. Lung Dis. 20, 1554\u20131561 (2016).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"33825_CR11","doi-asserted-by":"publisher","first-page":"589471","DOI":"10.1155\/2015\/589471","volume":"2015","author":"L Petrone","year":"2015","unstructured":"Petrone, L. et al. Blood or Urine IP-10 Cannot Discriminate between Active Tuberculosis and Respiratory Diseases Different from Tuberculosis inChildren. Biomed. Res. Int. 2015, 589471 (2015).","journal-title":"Biomed. Res. Int."},{"key":"33825_CR12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jinf.2013.02.004","volume":"66","author":"E Petruccioli","year":"2013","unstructured":"Petruccioli, E. et al. IFNgamma\/TNFalpha specific-cells and effector memory phenotype associate with active tuberculosis. J. Infect. 66, 475\u2013486 (2013).","journal-title":"J. Infect."},{"key":"33825_CR13","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1183\/13993003.01012-2016","volume":"48","author":"E Petruccioli","year":"2016","unstructured":"Petruccioli, E. et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur. Respir. J. 48, 1751\u20131763 (2016).","journal-title":"Eur. Respir. J."},{"key":"33825_CR14","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.4049\/jimmunol.1701737","volume":"200","author":"WE Whatney","year":"2018","unstructured":"Whatney, W. E. et al. A High Throughput Whole Blood Assay for Analysis of Multiple Antigen-Specific T Cell Responses in Human Mycobacterium tuberculosis Infection. J. Immunol. 200, 3008\u20133019 (2018).","journal-title":"J. Immunol."},{"key":"33825_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jiac.2017.09.012","volume":"24","author":"H Igari","year":"2018","unstructured":"Igari, H. et al. Lymphocyte subset analysis in QuantiFERON-TB Gold Plus and T-Spot.TB for latent tuberculosis infection in rheumatoid arthritis. J. Infect. Chemother. 24, 110\u2013116 (2018).","journal-title":"J. Infect. Chemother."},{"key":"33825_CR16","doi-asserted-by":"publisher","first-page":"e0193589","DOI":"10.1371\/journal.pone.0193589","volume":"13","author":"J Konig Walles","year":"2018","unstructured":"Konig Walles, J. et al. Performance of QuantiFERON-TB Gold Plus for detection of latent tuberculosis infection in pregnant women living in a tuberculosis- and HIV-endemic setting. PLoS One 13, e0193589 (2018).","journal-title":"PLoS One"},{"key":"33825_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/cid\/ciu795","volume":"60","author":"V Rozot","year":"2015","unstructured":"Rozot, V. et al. Combined use of Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis. Clin. Infect. Dis. 60, 432\u2013437 (2015).","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"33825_CR18","doi-asserted-by":"publisher","first-page":"1800153","DOI":"10.1183\/13993003.00153-2018","volume":"51","author":"Munyaradzi Musvosvi","year":"2018","unstructured":"Musvosvi, M. et al. T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation. Eur. Respir. J. 51, https:\/\/doi.org\/10.1183\/13993003.00153-2018. Print 2018 Mar (2018).","journal-title":"European Respiratory Journal"},{"key":"33825_CR19","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.4049\/jimmunol.1101122","volume":"187","author":"CL Day","year":"2011","unstructured":"Day, C. L. et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J. Immunol. 187, 2222\u20132232 (2011).","journal-title":"J. Immunol."},{"key":"33825_CR20","doi-asserted-by":"publisher","first-page":"e94949","DOI":"10.1371\/journal.pone.0094949","volume":"9","author":"CL Day","year":"2014","unstructured":"Day, C. L. et al. Patients with tuberculosis disease have Mycobacterium tuberculosis-specific CD8 T cells with a pro-apoptotic phenotype and impaired proliferative capacity, which is not restored following treatment. PLoS One 9, e94949 (2014).","journal-title":"PLoS One"},{"key":"33825_CR21","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1164\/rccm.200306-837OC","volume":"168","author":"DA Lewinsohn","year":"2003","unstructured":"Lewinsohn, D. A. et al. Mycobacterium tuberculosis-specific CD8+\u2009T cells preferentially recognize heavily infected cells. Am. J. Respir. Crit. Care Med. 168, 1346\u20131352 (2003).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"33825_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.imlet.2018.04.001","volume":"198","author":"T Chiacchio","year":"2018","unstructured":"Chiacchio, T. et al. Impact of antiretroviral and tuberculosis therapies on CD4(+) and CD8(+) HIV\/M. tuberculosis-specific T-cell in co-infected subjects. Immunol. Lett. 198, 33\u201343 (2018).","journal-title":"Immunol. Lett."},{"key":"33825_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jinf.2014.06.009","volume":"69","author":"T Chiacchio","year":"2014","unstructured":"Chiacchio, T. et al. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. J. Infect. 69, 533\u2013545 (2014).","journal-title":"J. Infect."},{"key":"33825_CR24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1164\/rccm.201107-1355OC","volume":"185","author":"C Lancioni","year":"2012","unstructured":"Lancioni, C. et al. CD8+ T cells provide an immunologic signature of tuberculosis in young children. Am. J. Respir. Crit. Care Med. 185, 206\u2013212 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"33825_CR25","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/eji.201243262","volume":"43","author":"V Rozot","year":"2013","unstructured":"Rozot, V. et al. Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease. Eur. J. Immunol. 43, 1568\u20131577 (2013).","journal-title":"Eur. J. Immunol."},{"key":"33825_CR26","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1183\/13993003.02033-2015","volume":"47","author":"L Barcellini","year":"2016","unstructured":"Barcellini, L. et al. First independent evaluation of QuantiFERON-TB Plus performance. Eur. Respir. J. 47, 1587\u20131590 (2016).","journal-title":"Eur. Respir. J."},{"key":"33825_CR27","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1183\/13993003.00510-2016","volume":"48","author":"L Barcellini","year":"2016","unstructured":"Barcellini, L. et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur. Respir. J. 48, 1411\u20131419 (2016).","journal-title":"Eur. Respir. J."},{"key":"33825_CR28","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jinf.2016.09.008","volume":"73","author":"E Petruccioli","year":"2016","unstructured":"Petruccioli, E. et al. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. J. Infect. 73, 588\u2013597 (2016).","journal-title":"J. Infect."},{"key":"33825_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tube.2017.06.002","volume":"106","author":"E Petruccioli","year":"2017","unstructured":"Petruccioli, E. et al. Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis (Edinb) 106, 38\u201343 (2017).","journal-title":"Tuberculosis (Edinb)"},{"key":"33825_CR30","unstructured":"QuantiFERON\u00ae-TB Gold Plus, ELISA Package Insert, QUIAGEN, http:\/\/www.quantiferon.com\/irm\/content\/PI\/QFT\/PLUS\/2PK-Elisa\/UK.pdf."},{"key":"33825_CR31","first-page":"1","volume":"59","author":"GH Mazurek","year":"2010","unstructured":"Mazurek, G. H. et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 59, 1\u201325 (2010).","journal-title":"MMWR Recomm Rep."},{"key":"33825_CR32","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1164\/rccm.201704-0817OC","volume":"196","author":"E Nemes","year":"2017","unstructured":"Nemes, E. et al. Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection. Am. J. Respir. Crit. Care Med. 196, 638\u2013648 (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"33825_CR33","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1164\/rccm.201203-0430OC","volume":"187","author":"JZ Metcalfe","year":"2013","unstructured":"Metcalfe, J. Z. et al. Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am. J. Respir. Crit. Care Med. 187, 206\u2013211 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"33825_CR34","first-page":"84","volume":"13","author":"M Pai","year":"2009","unstructured":"Pai, M. et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int. J. Tuberc. Lung Dis. 13, 84\u201392 (2009).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"33825_CR35","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tube.2017.11.014","volume":"108","author":"ED Pieterman","year":"2018","unstructured":"Pieterman, E. D. et al. A multicentre verification study of the QuantiFERON((R))-TB Gold Plus assay. Tuberculosis (Edinb) 108, 136\u2013142 (2018).","journal-title":"Tuberculosis (Edinb)"},{"issue":"3","key":"33825_CR36","doi-asserted-by":"publisher","first-page":"1601976","DOI":"10.1183\/13993003.01976-2016","volume":"49","author":"Arisu Kamada","year":"2017","unstructured":"Kamada, A. & Amishima, M. QuantiFERON-TB((R)) Gold Plus as a potential tuberculosis treatment monitoring tool. Eur. Respir. J. 49, https:\/\/doi.org\/10.1183\/13993003.01976-2016. Print 2017 Mar (2017).","journal-title":"European Respiratory Journal"},{"key":"33825_CR37","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1128\/JCM.02498-16","volume":"55","author":"HW Moon","year":"2017","unstructured":"Moon, H. W. et al. Evaluation of QuantiFERON-TB Gold-Plus in Health Care Workers in a Low-Incidence Setting. J. Clin. Microbiol. 55, 1650\u20131657 (2017).","journal-title":"J. Clin. Microbiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33825-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33825-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33825-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T10:44:12Z","timestamp":1671619452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33825-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["33825"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-33825-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"assertion":[{"value":"23 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.G. received an honorarium from Qiagen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15626"}}